The effects of heterologous immune globulins upon human cancer in vivo.
D000293:Adolescent; D000818:Animals; D000910:Antibodies, Heterophile / Q000627:therapeutic use; D004342:Drug Hypersensitivity; D005260:Female; D005266:Femoral Neoplasms / Q000188:drug therapy*; D006801:Humans; D007273:Injections, Intramuscular; D007938:Leukemia / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012516:Osteosarcoma / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use; D011687:Purines / Q000627:therapeutic use; D012756:Sheep; D013552:Swine; D005719:gamma-Globulins / Q000008:administration & dosage / Q000627:therapeutic use*
D000910:Antibodies, Heterophile; D011687:Purines; D005719:gamma-Globulins; D011241:Prednisone